Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1Lymphoid 1

Conditions

Multiple Myeloma 323Lymphoma 86Leukemia 63Precursor Cell Lymphoblastic Leukemia-Lymphoma 62Lymphoma, Non-Hodgkin 62Hodgkin Disease 60Leukemia, Lymphocytic, Chronic, B-Cell 58Neoplasms, Plasma Cell 56Leukemia, Myeloid, Acute 50Lymphoma, Mantle-Cell 47Myelodysplastic Syndromes 44Lymphoma, Follicular 44Myeloproliferative Disorders 42Lymphoma, Large B-Cell, Diffuse 42Lymphoma, B-Cell, Marginal Zone 40Burkitt Lymphoma 40Neoplasms 39Lymphoma, Large-Cell, Immunoblastic 38Primary Myelofibrosis 37Lymphoma, T-Cell, Cutaneous 35Sezary Syndrome 33Mycosis Fungoides 33Leukemia, Myeloid, Chronic-Phase 33Leukemia, Myeloid, Accelerated Phase 33Congenital Abnormalities 31Hematologic Neoplasms 30Blast Crisis 30Leukemia, Hairy Cell 29Breast Neoplasms 29Leukemia, Myelomonocytic, Chronic 27

Interventions

Dalteparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Fractures, Spontaneous × Plasma cell × Clear all
NCT00525057 2021-01-22

Dalteparin in Preventing DVT in Participants With Cancer

M.D. Anderson Cancer Center

Phase NA Completed
65 enrolled 14 charts
LymphoidPlasma cellSarcoma

Bone Neoplasms, Femoral Fractures, Fractures, Spontaneous, Lymphoma, Multiple Myeloma, Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡